Payment overview · 2025
General Payments
$504.77
20 reported records · 10 companies
Healthcare provider profile · identity verified
Steven M Kaplan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLAYTON, CA · NPI 1518073030
Verified facts
What the public records show
CMS Open Payments records show Steven M Kaplan, M.D. received $504.77 in general payments during 2025 across 20 reported records.
Exact Sciences Corporation accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $103.12 | 20.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.42 | 19.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $94.92 | 18.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.12 | 8.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.54 | 7.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.17 | 7.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.81 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.20 | 4.8% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $22.66 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.81 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $482.11 | 19 |
| Entertainment | $22.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $103.12 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.93 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.93 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.99 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.12 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.54 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $36.54 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 106 |
| Lisinopril | Lisinopril | 353 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 44 |
| Lorazepam | Lorazepam | 172 | 32 |
| Losartan Potassium | Losartan Potassium | 154 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 34 |
| Gabapentin | Gabapentin | 143 | 39 |
| Trazodone Hcl | Trazodone Hcl | 134 | 29 |
| Simvastatin | Simvastatin | 133 | 35 |
| Alprazolam | Alprazolam | 132 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 35 |
| Tramadol Hcl | Tramadol Hcl | 129 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 32 |
| Metformin Hcl | Metformin Hcl | 105 | 34 |
| Omeprazole | Omeprazole | 103 | 34 |
| Alendronate Sodium | Alendronate Sodium | 100 | 30 |
| Metformin Hcl Er | Metformin Hcl | 96 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 40 |
| Montelukast Sodium | Montelukast Sodium | 89 | 23 |
| Testosterone | Testosterone | 88 | 12 |
| Furosemide | Furosemide | 83 | 26 |
| Finasteride | Finasteride | 69 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 24 |
| Sertraline Hcl | Sertraline Hcl | 65 | 15 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Famotidine | Famotidine | 64 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 12 |
| Ozempic | Semaglutide | 59 | suppressed |
| Diazepam | Diazepam | 55 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 18 |
| Jardiance | Empagliflozin | 55 | 20 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 15 |
| Allopurinol | Allopurinol | 49 | 13 |
| Pregabalin | Pregabalin | 49 | 11 |
| Azelastine Hcl | Azelastine Hcl | 48 | 19 |
| Nystatin | Nystatin | 47 | 13 |
| Atenolol | Atenolol | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Eliquis | Apixaban | 42 | 14 |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Ibuprofen | Ibuprofen | 40 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 12 |
| Fenofibrate | Fenofibrate | 38 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 18 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Omnaris | Ciclesonide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $504.77 · 20 records | Exact Sciences Corporation | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, NFC-700, OCT OPHTHALMOSCOPE, OFEV, Ozempic, PANORAMIC OPHTHALMOSCOPE, QULIPTA, UBRELVY, VRAYLAR, Veozah, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error